| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100650 | Best Practice & Research Clinical Haematology | 2015 | 8 Pages |
Abstract
Using a case study of a 57-year-old man with relapsed/refractory precursor-B (pre-B) acute lymphoblastic leukemia (ALL), this review discusses treatment with immunoconjugates and autologous therapy in acute ALL. Three therapies—blinatumomab, inotuzumab, and CAR T cells—are considered here, each with advantages in specific clinical situations. These therapies represent some of the exciting advances that have been made in the treatment of ALL over the last several years.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anjali Advani,